Dopaminergic transmission in STOP null mice, J Neurochem, vol.94, pp.63-73, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-00380189
What can we Learn from the Disrupted in Schizophrenia 1 Interactome: Lessons for Target Identification and Disease Biology?, Novartis Found Symp, vol.289238, pp.208-224, 2008. ,
DOI : 10.1002/9780470751251.ch17
Effect of antipsychotic drugson DISC1 and dysbindin expression in mouse frontal cortex and hippocampus, J Neural Transm, 2006. ,
Behavioral Phenotypes of Disc1 Missense Mutations in Mice, Neuron, vol.54, issue.3, pp.387-402, 2007. ,
DOI : 10.1016/j.neuron.2007.04.015
NMDA Receptor Function, Neuroplasticity, and the Pathophysiology of Schizophrenia, Int Rev Neurobiol, vol.59, pp.491-515, 2004. ,
DOI : 10.1016/S0074-7742(04)59019-0
Genomic Structure and Chromosomal Mapping of the Mouse STOP Gene (Mtap6), Biochemical and Biophysical Research Communications, vol.243, issue.3, pp.791-797, 1998. ,
DOI : 10.1006/bbrc.1998.8179
Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia, Molecular Psychiatry, vol.4, issue.5, pp.418-446, 1999. ,
DOI : 10.1038/sj.mp.4000581
Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice, Journal of Psychopharmacology, vol.105, issue.6, pp.635-679, 2007. ,
DOI : 10.1177/0269881106068825
URL : https://hal.archives-ouvertes.fr/inserm-00380032
Animal models with construct validity for schizophrenia, Behavioural Pharmacology, vol.1, issue.6, pp.469-490, 1990. ,
DOI : 10.1097/00008877-199000160-00001
Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics, Clin Pharm, vol.9, pp.682-707, 1990. ,
STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating, Behavioural Brain Research, vol.163, issue.2, pp.257-64, 2005. ,
DOI : 10.1016/j.bbr.2005.05.012
URL : https://hal.archives-ouvertes.fr/inserm-00380197
The Synaptic Hypothesis of Schizophrenia, Neuron, vol.39, issue.2, pp.205-221, 2003. ,
DOI : 10.1016/S0896-6273(03)00423-9
Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans, Proceedings of the National Academy of Sciences, vol.104, issue.36, 2007. ,
DOI : 10.1073/pnas.0704774104
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1964873
A Review of Disrupted-in-Schizophrenia-1 (disc1): Neurodevelopment, Cognition, and Mental Conditions, Biological Psychiatry, vol.59, issue.12, pp.1189-97, 2006. ,
DOI : 10.1016/j.biopsych.2006.03.065
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009. ,
DOI : 10.1016/S0140-6736(08)61764-X
URL : http://mediatum.ub.tum.de/doc/824604/document.pdf
Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia, Am J Hum Genet, vol.73, pp.34-48, 2003. ,
Role of DISC1 in neural development and schizophrenia, Current Opinion in Neurobiology, vol.17, issue.1, pp.95-102, 2007. ,
DOI : 10.1016/j.conb.2007.01.007
Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia, European Archives of Psychiatry and Clinical Neuroscience, vol.107, issue.5, pp.151-63, 2009. ,
DOI : 10.1007/s00406-008-0847-2
Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1), Neurochemistry International, vol.51, issue.2-4, pp.165-72, 2007. ,
DOI : 10.1016/j.neuint.2007.06.018
What's atypical about atypical antipsychotic drugs?, Current Opinion in Pharmacology, vol.4, issue.1, pp.53-60, 2004. ,
DOI : 10.1016/j.coph.2003.09.010
Challenges for translational psychopharmacology research???some basic principles, Psychopharmacology, vol.21, issue.3, pp.291-301, 2008. ,
DOI : 10.1007/s00213-008-1198-4
S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine, J Pharmacol Exp Ther, vol.298, pp.581-91, 2001. ,
Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse, Trends in Neurosciences, vol.24, issue.8, 2001. ,
DOI : 10.1016/S0166-2236(00)01862-2
Schizophrenia, The Lancet, vol.363, issue.9426, pp.2063-72, 2004. ,
DOI : 10.1016/S0140-6736(04)16458-1
A combined marble burying???locomotor activity test in mice: A practical screening test with sensitivity to different classes of anxiolytics and antidepressants, European Journal of Pharmacology, vol.547, issue.1-3, pp.106-121, 2006. ,
DOI : 10.1016/j.ejphar.2006.07.015
Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice, European Journal of Pharmacology, vol.324, issue.2-3, 1997. ,
DOI : 10.1016/S0014-2999(97)00067-8
Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia, British Journal of Pharmacology, vol.9, issue.Suppl. 5, pp.2531-2538, 1995. ,
DOI : 10.1111/j.1476-5381.1995.tb15106.x
Schizophrenia: genes at last?, Trends in Genetics, vol.21, issue.9, pp.518-543, 2005. ,
DOI : 10.1016/j.tig.2005.06.011
Schizophrenia: a genetic disorder of the synapse?, BMJ, vol.330, issue.7484, pp.158-167, 2005. ,
DOI : 10.1136/bmj.330.7484.158
Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial, Nature Medicine, vol.43, issue.9, pp.1102-1109, 2007. ,
DOI : 10.1038/nm1632
Treatment of cognitive dysfunction in schizophrenia, Clinical Therapeutics, vol.27, pp.25-37, 2005. ,
DOI : 10.1016/j.clinthera.2005.07.015
Behavioural despair in rats: A new model sensitive to antidepressant treatments, European Journal of Pharmacology, vol.47, issue.4, pp.379-91, 1978. ,
DOI : 10.1016/0014-2999(78)90118-8
Behavioral despair in mice: a primary screening test for antidepressants, Arch Int Pharmacodyn Ther, vol.229, pp.327-363, 1977. ,
Cognitive impairments in the STOP null mouse model of schizophrenia., Behavioral Neuroscience, vol.121, issue.5, pp.826-861, 2007. ,
DOI : 10.1037/0735-7044.121.5.826
URL : https://hal.archives-ouvertes.fr/inserm-00380034
Effects of systemic administration of ??-casomorphin-5 on learning and memory in mice, European Journal of Pharmacology, vol.530, issue.1-2, pp.81-88, 2006. ,
DOI : 10.1016/j.ejphar.2005.11.014
Social cognition in schizophrenia: Relationships with neurocognition and negative symptoms, Schizophrenia Research, vol.90, issue.1-3, pp.316-340, 2007. ,
DOI : 10.1016/j.schres.2006.09.028
Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia, Schizophrenia Research, vol.84, issue.2-3, pp.244-52, 2006. ,
DOI : 10.1016/j.schres.2006.03.017
DISC1 Regulates Neurotrophin-Induced Axon Elongation via Interaction with Grb2, Journal of Neuroscience, vol.27, issue.1, pp.4-14, 2007. ,
DOI : 10.1523/JNEUROSCI.3825-06.2007
Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin, Human Molecular Genetics, vol.15, issue.20, pp.3041-54, 2006. ,
DOI : 10.1093/hmg/ddl246
URL : http://hmg.oxfordjournals.org/cgi/content/short/15/20/3041
3-3epsilon complex through kinesin-1, DISC1 regulates the transport of the NUDEL, pp.15-26, 2007. ,
Clozapine, Olanzapine, Risperidone, and Haloperidol in the Treatment of Patients With Chronic Schizophrenia and Schizoaffective Disorder, American Journal of Psychiatry, vol.159, issue.2, pp.255-62, 2002. ,
DOI : 10.1176/appi.ajp.159.2.255
-tetrahydro-1,3-dioxolo 4,5-g isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in, 2006. ,
URL : https://hal.archives-ouvertes.fr/hal-00109100